Intravenous cell infusion is an outpatient procedure requiring 30–60 minutes. Mild fever, transient headache, or fatigue may occur within 24–48 hours post-infusion; these resolve with rest and simple analgesia. Intra-arterial delivery requires brief neuroradiology-based anaesthesia and 4–6 hours observation; same-day or next-day discharge is typical. No prolonged immobility is required. Concurrent intensive physiotherapy, speech therapy, and cognitive rehabilitation typically intensify post-cell therapy to capitalise on heightened neural plasticity. Overall downtime is minimal; patients resume outpatient rehabilitation within 24–48 hours.
Published trials of intravenous or intra-arterial stem cell infusion in chronic stroke (months to years post-event) report motor improvement in 45–65% of participants, quantified by Fugl-Meyer Assessment score gains of 5–15 points over 6–12 months. Language recovery (Aphasia Quotient) improves in 40–55% of stroke-aphasia patients receiving neurogenic cell therapy. One phase II trial (120 patients, 6–36 months post-stroke) demonstrated sustained motor gains at 24-month follow-up in 60% of treated versus 30% of sham-injected controls. Imaging studies show increased activation in perilesional cortex and contralesional motor areas post-treatment. Mechanisms appear to involve both direct cell replacement and systemic immunomodulation rather than exclusive structural reconstitution.
האם אני מועמד? → · Stroke Recovery: full overview → · עלות התאוששות מתקף שבץ → · Cost →
בדוקה רפואית על ידי צוות העריכה של StemCellAtlas עם Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) של קליניקת השותף Stem Plus (סופיה), כנגד הנחיות ISSCR, FDA ו-EMA. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם